Epalrestat improves motor symptoms by reducing oxidative stress and inflammation in the reserpine induced mouse model of Parkinson's disease.
Epalrestat
Parkinson's disease
bradykinesia
glutathione
oxidative‐stress
Journal
Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
07
09
2019
revised:
12
11
2019
accepted:
06
12
2019
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting a large number of elderly people worldwide. The current therapies for PD are symptom-based; they do not provide a cure but improve the quality of life. Muscular dysfunction is the hallmark clinical feature of PD and oxidative stress and inflammation play a critical role in its pathogenesis. Epalrestat is used for the treatment of diabetic neuropathy and is known to improve antioxidative defense mechanisms in the CNS. Therefore, in this study, we investigated the role of Epalrestat in the reserpine induced mouse model of PD. We used Swiss Albino mice for the PD model and tested for akinesia/bradykinesia, muscular rigidity, palpebral ptosis, and tremor, as well as conducting swim and open field tests. Brain samples were used to determine oxidative stress parameters and infiltration of immune cells. Epalrestat treatment significantly improved akinesia and bradykinesia, muscular dysfunctions, tremor level, and gait functions compared to the reserpine group. It also improved the latency in the swim test. Eplarestat significantly reduced lipid peroxidation and NO concentration in different brain tissues and increased the activity of antioxidative enzymes, glutathione, catalase, and superoxide dismutase. Furthermore, Epalrestat reduced neuroinflammation by reducing the number of infiltrating immune cells. Eplarestat improves muscular dysfunction in PD by reducing oxidative stress and inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting a large number of elderly people worldwide. The current therapies for PD are symptom-based; they do not provide a cure but improve the quality of life. Muscular dysfunction is the hallmark clinical feature of PD and oxidative stress and inflammation play a critical role in its pathogenesis. Epalrestat is used for the treatment of diabetic neuropathy and is known to improve antioxidative defense mechanisms in the CNS. Therefore, in this study, we investigated the role of Epalrestat in the reserpine induced mouse model of PD.
METHOD
METHODS
We used Swiss Albino mice for the PD model and tested for akinesia/bradykinesia, muscular rigidity, palpebral ptosis, and tremor, as well as conducting swim and open field tests. Brain samples were used to determine oxidative stress parameters and infiltration of immune cells.
RESULTS
RESULTS
Epalrestat treatment significantly improved akinesia and bradykinesia, muscular dysfunctions, tremor level, and gait functions compared to the reserpine group. It also improved the latency in the swim test. Eplarestat significantly reduced lipid peroxidation and NO concentration in different brain tissues and increased the activity of antioxidative enzymes, glutathione, catalase, and superoxide dismutase. Furthermore, Epalrestat reduced neuroinflammation by reducing the number of infiltrating immune cells.
CONCLUSION
CONCLUSIONS
Eplarestat improves muscular dysfunction in PD by reducing oxidative stress and inflammation.
Identifiants
pubmed: 32318655
doi: 10.1002/ame2.12097
pii: AME212097
pmc: PMC7167235
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9-21Informations de copyright
© 2019 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Déclaration de conflit d'intérêts
None.
Références
Sleep Med Rev. 2018 Oct;41:101-112
pubmed: 29449121
Crit Rev Food Sci Nutr. 2013;53(11):1157-67
pubmed: 24007420
Mov Disord. 1996 May;11(3):261-7
pubmed: 8723142
Diabetes Care. 1997 Jun;20(6):995-8
pubmed: 9167113
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Nutrients. 2012 Oct 09;4(10):1399-440
pubmed: 23201762
Nat Rev Drug Discov. 2007 Aug;6(8):662-80
pubmed: 17667957
JAMA. 2014 Apr 23-30;311(16):1670-83
pubmed: 24756517
Lancet Neurol. 2007 Sep;6(9):782-92
pubmed: 17689146
Ann N Y Acad Sci. 2003 Jun;991:214-28
pubmed: 12846989
Exp Neurol. 2001 Jun;169(2):400-6
pubmed: 11358453
Biol Pharm Bull. 2016 Sep 1;39(9):1523-30
pubmed: 27439473
Neural Regen Res. 2016 Feb;11(2):345-51
pubmed: 27073391
J Biol Chem. 2008 Dec 12;283(50):34887-95
pubmed: 18922792
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
J Neurochem. 2008 May;105(3):714-24
pubmed: 18194211
J Pharmacol Exp Ther. 2007 Sep;322(3):913-22
pubmed: 17565007
Adv Protein Chem Struct Biol. 2012;88:69-132
pubmed: 22814707
Toxicol Sci. 2016 Jun;151(2):388-402
pubmed: 27026709
Nitric Oxide. 2000 Oct;4(5):534-9
pubmed: 11020342
Neurotox Res. 2012 Nov;22(4):251-64
pubmed: 22488161
Oxid Med Cell Longev. 2012;2012:132146
pubmed: 22701754
J Biol Chem. 2000 Aug 25;275(34):26096-101
pubmed: 10846169
Nature. 1957 Nov 30;180(4596):1200
pubmed: 13483658
Redox Biol. 2013 Nov 19;2:15-21
pubmed: 24363998
Neurobiol Aging. 1997 Nov-Dec;18(6):623-9
pubmed: 9461060
Oxid Med Cell Longev. 2015;2015:314560
pubmed: 26576219
Anal Biochem. 1982 Oct;126(1):131-8
pubmed: 7181105
Arzneimittelforschung. 1965 Feb;15:104-17
pubmed: 14268414
Behav Brain Res. 2007 Feb 12;177(1):109-16
pubmed: 17129617
Rev Neurosci. 2013;24(3):293-300
pubmed: 23645123
J Biol Chem. 1972 May 25;247(10):3170-5
pubmed: 4623845
Chem Phys Lipids. 2004 Mar;128(1-2):117-24
pubmed: 15037157
Trends Neurosci. 1993 Aug;16(8):323-8
pubmed: 7691008
Ann N Y Acad Sci. 2008 Dec;1147:93-104
pubmed: 19076434
Neuropsychopharmacology. 2001 Feb;24(2):170-82
pubmed: 11120399
Ann Neurol. 2003;53 Suppl 3:S26-36; discussion S36-8
pubmed: 12666096
Brain Pathol. 2015 Jul;25(4):377-90
pubmed: 25726735
Front Neuroanat. 2015 Apr 02;9:32
pubmed: 25883554
Brain Res. 2008 Jan 16;1189:215-8
pubmed: 18061150
Brain Res Bull. 1991 Feb;26(2):317-20
pubmed: 1901508
J Epidemiol. 2009;19(6):281-93
pubmed: 19801887
Nature. 1988 Jul 28;334(6180):345-8
pubmed: 2899295
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
J Clin Immunol. 2004 Nov;24(6):683-92
pubmed: 15622453
Trends Neurosci. 2003 Jul;26(7):345-6
pubmed: 12850429
Nat Rev Neurosci. 2007 Jan;8(1):57-69
pubmed: 17180163
Diabetes. 2005 Mar;54(3):818-29
pubmed: 15734861
IUBMB Life. 2003 Jun;55(6):329-35
pubmed: 12938735
Neurobiol Aging. 2017 Feb;50:119-133
pubmed: 27960106
Cell. 1996 Jul 12;86(1):159-71
pubmed: 8689683
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76
pubmed: 18344392
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6227-32
pubmed: 12732720
Psychopharmacology (Berl). 2002 Jun;161(4):340-7
pubmed: 12073160
Blood. 2005 Jul 15;106(2):584-92
pubmed: 15811956
Chem Biol Interact. 2011 May 30;191(1-3):330-8
pubmed: 21354119
Pharmacol Biochem Behav. 2008 Feb;88(4):465-72
pubmed: 18001823
Int Immunol. 1990;2(8):719-24
pubmed: 1982067
Transl Neurodegener. 2015 Oct 12;4:19
pubmed: 26464797
J Neurosci. 2007 Dec 19;27(51):13997-4006
pubmed: 18094238
Mol Neurodegener. 2009 Jun 05;4:24
pubmed: 19500376
Neurology. 2006 May 23;66(10 Suppl 4):S24-36
pubmed: 16717250
Arzneimittelforschung. 1977;27(12):2326-32
pubmed: 580044
Ann Neurol. 2005 Oct;58(4):495-505
pubmed: 16178023
J Psychopharmacol. 2000;14(4):406-8
pubmed: 11198060
Eur J Hum Genet. 2008 Aug;16(8):941-54
pubmed: 18285828
Mov Disord. 2011 May;26(6):1049-55
pubmed: 21626550
Eur J Pharmacol. 2006 Mar 27;535(1-3):199-207
pubmed: 16546164
Front Neuroanat. 2015 Jul 08;9:91
pubmed: 26217195
Behav Brain Res. 2005 Sep 8;163(2):159-67
pubmed: 15941598
Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1716-23
pubmed: 10894808
Brain Res Bull. 2004 Dec 15;64(4):339-45
pubmed: 15561469
Nature. 1954 Nov 27;174(4439):1015
pubmed: 13214063
J Neurosci. 2004 Sep 15;24(37):8019-28
pubmed: 15371502
J Biol Chem. 2013 Jul 19;288(29):20843-55
pubmed: 23744073
J Diabetes Complications. 2002 Sep-Oct;16(5):321-6
pubmed: 12200074
Endocrinology. 1998 Aug;139(8):3404-8
pubmed: 9681489
Br J Pharmacol. 2000 Feb;129(3):541-6
pubmed: 10711353
Science. 2008 Aug 8;321(5890):848-51
pubmed: 18687967
Nat Rev Neurosci. 2003 May;4(5):365-75
pubmed: 12728264
J Neuropsychol. 2013 Sep;7(2):193-224
pubmed: 24007368
Neurology. 2004 Jan 27;62(2):177-80
pubmed: 14745050
J Parkinsons Dis. 2013;3(4):461-91
pubmed: 24252804
Exp Neurobiol. 2013 Mar;22(1):11-7
pubmed: 23585717
Brain Res Bull. 1996;39(6):367-72
pubmed: 9138746
Eur J Biochem. 2000 Aug;267(16):4904-11
pubmed: 10931172
Annu Rev Neurosci. 1999;22:123-44
pubmed: 10202534
Front Neurol. 2017 Jul 18;8:329
pubmed: 28769865
Mov Disord. 1989;4(4):297-302
pubmed: 2811889